Dr. Bo Luo 罗波
Chief Physician
Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of gastrointestinal, urogenital, breast, lymphoma, soft tissue, lung, and head and neck tumors.
Dr. Luo is Chief Physician and holds a medical doctorate. Roles include Deputy Director of the Radiotherapy Center and Director of the First Abdominal Radiotherapy Ward. A visiting scholar at MD Anderson Cancer Center, Dr. Luo leads one National Natural Science Foundation project and participates in four. Research focuses on targeted therapy resistance, immunotherapy, and radiobiology.
Professional roles
- Member, Targeted Therapy Committee, Hubei Anti-Cancer Association
- Member, Radiotherapy Group, Colorectal Cancer Professional Committee, China Anti-Cancer Association
- Member, Gastric and Colorectal Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Luo Bo). Papers usually list the name as Bo Luo or Luo B.
Selected publications
19 papers on PubMed matched by name and affiliation; 11 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Immunol Immunother, 2025 (senior author): Salvianic acid A enhances anti-PD-1 therapy by promoting HEV-mediated stem-like CD8 T cells infiltration in TNBC. PubMed 40586931
- Discov Oncol, 2025 (senior author): Segmental bronchi radiation dose affected the progression of radiation pneumonitis in lung cancer patients. PubMed 40380076
- Immunotherapy, 2025 (senior author): A case report of mesalazine alleviating diarrhea in a patient with nasopharyngeal cancer after tislelizumab treatment. PubMed 40350385
- Mol Carcinog, 2025 (first author): HMGB3 Contributes to Anti-PD-1 Resistance by Inhibiting IFN-γ-Driven Ferroptosis in TNBC. PubMed 39660968
- Front Oncol, 2025 (senior author): Efficacy of anlotinib and chemotherapy combination as neoadjuvant therapy in the treatment of pulmonary artery intimal sarcoma: a case report. PubMed 40078190
- Front Nutr, 2025 (senior author): Association of oxidative balance score with metabolic syndrome and its components in middle-aged and older individuals in the United States. PubMed 39980681
- Front Pharmacol, 2024 (senior author): Targeting cuproptosis with nano material: new way to enhancing the efficacy of immunotherapy in colorectal cancer. PubMed 39691393
- Int Immunopharmacol, 2024 (first author): ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC. PubMed 39116492
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion